Phreesia, Inc. (NYSE: PHR) Chief Financial Officer Randy Rasmussen sold 2,228 shares in a trade dated Wednesday, January 19. The stock was sold at an average price of $32.66, for a total transaction of $72,766.48. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of PHR traded down $0.15 during the midday session on Friday, hitting $30.85. 765,805 shares of the stock trade in hands, compared to its average volume of 583,265. The stock has a market capitalization of $1.58 billion, a P/E ratio of -19.08 and a beta of 1 ,27. The stock’s fifty-day moving average is $48.25 and its two-hundred-day moving average is $60.33. Phreesia, Inc. has a 52-week low of $29.36 and a 52-week high of $81.59. The company has a debt ratio of 0.01, a current ratio of 7.15 and a quick ratio of 7.15.

Phreesia Inc (NYSE:PHR) last released its quarterly earnings data on Wednesday, December 8. The company reported ($0.46) earnings per share (EPS) for the quarter, beating Thomson Reuters consensus estimate of ($0.47) by $0.01. Phreesia had a negative net margin of 40.51% and a negative return on equity of 18.66%. The company posted revenue of $55.90 million for the quarter, versus a consensus estimate of $48.75 million. In the same quarter a year earlier, the company posted ($0.17) earnings per share. The company’s revenue for the quarter increased by 45.2% compared to the same quarter last year. As a group, equity analysts expect Phreesia, Inc. to post EPS of -2.49 for the current fiscal year.

Institutional investors and hedge funds have recently been buying and selling shares of the company. Clearstead Advisors LLC acquired a new position in shares of Phreesia during the third quarter worth approximately $29,000. Advisory Services Network LLC acquired a new equity position in Phreesia during the second quarter worth approximately $44,000. Pinz Capital Management LP acquired a new position in shares of Phreesia during the second quarter valued at approximately $123,000. O Shaughnessy Asset Management LLC increased its holdings of Phreesia shares by 18.6% during the third quarter. O Shaughnessy Asset Management LLC now owns 2,121 shares of the company valued at $131,000 after acquiring 332 additional shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its equity stake in Phreesia by 23.0% during the third quarter. Nisa Investment Advisors LLC now owns 2,140 shares of the company valued at $132,000 after acquiring 400 additional shares in the last quarter. Hedge funds and other institutional investors own 95.78% of the company’s shares.

Several analysts have commented on the title. Jefferies Financial Group began covering Phreesia shares in a report on Wednesday, December 1. They issued a “buy” rating and a price target of $70.00 for the company. Citigroup lowered its price target on Phreesia from $72.00 to $54.00 and set a “neutral” rating on the stock in a Friday, Dec. 10 report. Needham & Company LLC lowered its price target on Phreesia from $81.00 to $65.00 and set a “buy” rating on the stock in a Thursday, Dec. 9 report. SVB Leerink downgraded Phreesia from an “outperforming” rating to a “market performing” rating and lowered its target price for the company from $57.00 to $41.00 in a Thursday, January 6 report. Finally, the Royal Bank of Canada cut its price target on Phreesia from $60.00 to $51.00 and set an “industry performance” rating for the company in a Thursday, Dec. 9 research report. Four equity research analysts gave the stock a hold rating and ten gave the company a buy rating. Based on data from MarketBeat.com, Phreesia currently has an average rating of “Buy” and an average price target of $64.15.

Phreesia Company Profile

Phreesia, Inc is a healthcare software company, which provides patient registration solutions for medical practices. The Company offers appointments, clinical support, onboarding, registration, patient activation, analytics and reporting, revenue cycle, patient surveys, and privacy and security products.

Recommended Story: How to Find Quick Ratio Components

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Phreesia right now?

Before you consider Phreesia, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes big…and Phreesia wasn’t on the list.

Although Phreesia currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here